GlassScriptPhysician profile
Ariff Admani
NPI 1770554263
$1,697.92
in general payments reported to CMS, 2019-2025
7 companies · $527 in 2025
The $527 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $406 · 2023: $35.38 · 2024: $370 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $854 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $854.34 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $723.33 | 2023-2025 | Biktarvy, Epclusa |
| Allergan, INC. | $400.94 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $232.55 | 2019-2020 | |
| Royal Biologics, INC. | $132.10 | 2020 | |
| Shionogi INC | $110.16 | 2025 | Fetroja |
| Astellas Pharma US INC | $77.99 | 2025 | |
| Becton, Dickinson and Company | $20.85 | 2024 | Bd Onclarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ariff Admani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.